Should you buy Capricor Therapeutics stock now?
No, the technical signal for Capricor Therapeutics is currently Strong Sell. Capricor Therapeutics trades at $7.24 as of Nov 3, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -0.496 with rising momentum (signal: -0.608); RSI is at 51.0 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average). The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Capricor Therapeutics stock?
There is currently no active analyst price target for Capricor Therapeutics.
Is Capricor Therapeutics a dividend stock?
No, Capricor Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Capricor Therapeutics stock?
Capricor Therapeutics is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 393.8%, which classifies the stock as Extremely speculative.
Is Capricor Therapeutics overvalued?
Capricor Therapeutics has the following valuation ratios: a P/S ratio of 25.1, a P/B ratio of 1.5.
Is Capricor Therapeutics overbought?
No, Capricor Therapeutics is not overbought. RSI is at 51.0 (neutral zone). The technical indicators show: RSI is at 51.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 6.4% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Capricor Therapeutics earnings report?
Capricor Therapeutics reports its next earnings on November 9, 2026. The stock currently trades at $7.24.
Is Capricor Therapeutics shorted?
Yes, Capricor Therapeutics is shorted with 37.7% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Capricor Therapeutics stock?
Yes, insiders are net buyers of Capricor Therapeutics – they are buying more shares than they are selling. Across the last 20 reported transactions, the split is 6 purchases and 14 sales, with a net 7,418,900 $ bought. Active buyers include Nippon Shinyaku Co Ltd, Musket David B, COLLIER EARL M JR and others. In our study of insider purchases, however, the typical purchase did not beat the market over the following 3 months.
Is Capricor Therapeutics a good stock?
Based on our total score, Capricor Therapeutics is rated as a disastrous stock with a total score of 12 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 20/100, Quality: 14/100, Momentum: 3/100. Whether now is the time to buy is a separate question: the technical signal is Strong Sell. Whether Capricor Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Capricor Therapeutics stock?
The outlook for Capricor Therapeutics based on current data: the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Nov 9, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Capricor Therapeutics stock rising?
Capricor Therapeutics is rising right now. The technical indicators show: the price is 6.4% above the 20-day average; short interest is 37.7% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Capricor Therapeutics go?
There is currently no active analyst price target for Capricor Therapeutics. The stock has traded between $2.96 and $40.37 over the last 52 weeks. The price is 82.1% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Capricor Therapeutics fall?
The stock has traded as low as $2.96 over the last 52 weeks — that is 59.1% below the current price of $7.24. The biggest decline (drawdown) in the same period was 92.7% from high to low. Within a year, the price typically swings about ±393.8% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Capricor Therapeutics do?
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead produ... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Capricor Therapeutics as an investment.
Did Capricor Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Capricor Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Capricor Therapeutics making money or losing money?
We have no current profitability data for Capricor Therapeutics. See the latest report in the earnings history above.
Can Capricor Therapeutics go bankrupt?
The bankruptcy risk of Capricor Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is 0.17 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 17% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Capricor Therapeutics have a lot of debt?
No, Capricor Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 17%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.